

日期

100年 1月 8日

內容摘要：

- (填寫說明：1. 如有附件請註明，如簡報檔、全文檔等
- 2. 需有問題與討論：請註明姓名並包含醫學倫理及 EBM 之應用
- 3. 需有總結，請註明做結論者【主持人】姓名
- 4. 請自行編排頁碼)

時間：100. 1. 8.

地點：同心園

主持人：PGY 姜慶祥 / PGY 許韶. 芸 / F 陳欣伶

紀錄：R= 朱建勳

<Topic>

Journal reading = 1. heart failure and COPD = diagnosis, pitfall and epidemiology  
 2. Risk of death associated with recently diagnosed COPD.

<Q & A>

F 陳欣伶 Q = Diagnosis of COPD.

PGY 吳子翔 A = clinical feature = cough ↑, sputum ↑, SOB ↑.  
lung function test = obstructive and restrictive defect.

F 陳欣伶 Q = Diagnosis of heart failure

PGY 陳嘉仰 A = Framingham criteria.  
heart echo = LV dysfunction, regurgitation

F 陳欣伶 Q = BNP level interpretation

PGY 陳念維 A = BNP < 100 → less likely heart failure.  
> 500 → heart failure.

F 陳欣伶 Q = right heart failure clinical feature

PGY 陳念維 A = body hepatic congestion, JVD.

F 陳欣伶 Q = lung function test in heart failure.

PGY 郭麗君 A = FEV1 也會 ↓ → may overdiagnose COPD.

F 陳欣伶 Q = relation between COPD and HF.

R 游壽寧 A = 有 heart failure 的人 COPD rate 也較高. (25% vs 13%)  
COPD → systemic inflammation → atherosclerosis → HF ↑  
且會互相 ↑ hospital stay, readmission

內容摘要 (續):

F 陳欣伶 Q: Effect of ~~ICS~~ inhaled corticosteroid (ICS)

R 周光遠 A: ↓ mortality.

F 陳欣伶 Q: effect of SABA

R 蘇法解 A: Rescue therapy. 但不影響 long term survival.

F 陳欣伶 Q: ~~ipr~~ effect of ipratropium

R 朱建勳 A: ↑ cardiovascular death and all cause mortality

F 陳欣伶 Q: effect of long acting  $\beta$ -agonist (LABA)?

R 蘇法解 A: ↓ all cause mortality

F 陳欣伶 Q: effect of theophylline.

R 朱建勳 A: ↑ mortality → may related to disease severity.

<EBM and ethics>

F 陳欣伶: = studies design of "risk for death associated with medication of most diagnosed COPD"

R 蘇法解 = ~~retrospective~~ nested case control study.

<Take home message>

1. Heart failure and COPD may mask each other.

2. COPD drugs may affect mortality.

<key point>

1. COPD, CHF 都是 clinical diagnosis

2. Clinical use of combi ~~may~~ need adjust. 記錄 = R 朱建勳.